BUSINESS
Eli Lilly
BUSINESS
Wegovy-maker Novo Nordisk to cut 9,000 jobs in restructuring
BUSINESS
Novo Nordisk woes prompt Denmark to slash country’s 2025 growth forecast
BUSINESS
Eli Lilly temporarily halts UK shipments of weight-loss drug Mounjaro
BUSINESS
S&P 500 ends higher as Trump escalates attack on Fed
BUSINESS
US futures edge up as Fed shake-up stokes dovish bets
BUSINESS
Wall Street stocks up as market shrugs off tariff increases
BUSINESS
Wegovy maker Novo Nordisk to reduce costs after US$95bil stock loss
BUSINESS
Wall Street futures stabilise after Friday’s rout
WORLD
US plans Medicare, Medicaid coverage for weight-loss drugs
BUSINESS
Novo Nordisk’s shares extend losses, erasing nearly all gains since Wegovy launch
BUSINESS
Obesity drug maker Novo Nordisk ousts CEO as competition weighs
BUSINESS
US stocks mixed as Trump eyes trade deal, rips Powell
BUSINESS
Investors seek answers on Novo Nordisk’s next-gen obesity drug CagriSema
BUSINESS
Novo, Lilly shares rise as Biden proposes obesity care coverage
BUSINESS
US FDA to reconsider decision barring compounded versions of Lilly weight loss drug
BUSINESS
Novo, Lilly shares fall after Biden calls for cheaper obesity drugs
BUSINESS
Zepbound resolves sleep apnea in up to 52% of patients, says Lilly
BUSINESS
Weight-loss drug forecasts jump to US$150bil as supply grows
BUSINESS
Lilly’s Zepbound surpasses Wegovy in new US prescriptions for 1st time
BUSINESS
US FDA delays decision on Lilly’s Alzheimer’s drug
BUSINESS
Lilly’s weight-loss drug Zepbound gets US, UK approval to rival Wegovy
HEALTH & FAMILY
‘Remarkable’ Alzheimer’s drug reduces cognitive decline
BUSINESS